When Can a Stroke Patient Be Administered a Cord Blood Based Stroke Treatment?
In the recent study conducted at Duke University and Houston Methodist, ten individuals were transfused with a single dose of allogeneic cord blood 3-9 days after an ischemic stroke.
After 12-months, there were no adverse events reported indicating that the transfusion so close to the stroke event was well tolerated.
In fact, the individual who was administered the cord blood three days after the stroke jumped two levels on the Rankin Scale.
His original Rankin Scale baseline was 4, which is defined as a moderately severe disability. The individual was unable to attend to his own bodily needs without assistance and was unable to walk unassisted.
At three months, he was classified as a 2 on the Rankin Scale which is defined as a slight disability. The patient was able to look after his own affairs without assistance but was unable to carry out all previous activities prior to his stroke.
The study suggests that a cord blood treatment administered between three and ten days after an ischemic stroke is safe, well tolerated and feasible.
Stem Cells Translational Medicine, 2018 May 12
“Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase 1 Safety Study.” Laskowitz DT, Bennett ER, Durham RJ, Volpi JJ, Wiese JR, Frankel M, Shpall E, Wilson JM, Troy J, Kurtzberg J.